Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27862677 | 0.88 | ALOX5 (0.47) | NPC1RAB9ACA12CA9LMNA | |
| SCHEMBL15514631 | 0.88 | NPC1 (0.47) | NPC1RAB9ACA12CA9LMNA | |
| SCHEMBL6254668 | 0.86 | NPC1 (0.46) | NPC1RAB9ACA12CA9LMNA | |
| SCHEMBL28908035 | 0.86 | NPC1 (0.50) | NPC1RAB9ACA12CA9LMNA | |
| SCHEMBL28716329 | 0.85 | KMT2A (0.51) | LMNATSHRSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL5544624 | 0.82 | TAAR1 (0.48) | NPC1RAB9AALDH1A1KMT2AMEN1 | |
| SCHEMBL3362411 | 0.82 | NPC1 (0.46) | NPC1RAB9ACA12CA9LMNA | |
| Acetic Acid SCHEMBL27312873 | 0.81 | GRIN2D (0.49) | NPC1RAB9ACA12CA9LMNA | |
| SCHEMBL20158167 | 0.80 | TSHR (0.43) | NPC1RAB9ACA12CA9LMNA | |
| SCHEMBL6872168 | 0.79 | NPC1 (0.40) | NPC1RAB9ACA12CA9LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9102704-B2 | Synthesis method and intermediates useful in the preparation of pyrrolobenzodiazepines | SPIROGEN SARL (CH) | 2015-08-11 | — | — | US | claimed |
| US-20140275522-A1 | SYNTHESIS METHOD AND INTERMEDIATES USEFUL IN THE PREPARATION OF PYRROLOBENZODIAZEPINES | SPIROGEN SÁRL (CH) | 2014-09-18 | — | — | US | claimed |
| EP-2956437-B1 | ALBICIDIN DERIVATIVES FOR THE TREATMENT OF BACTERIAL INFECTIONS | UNIV BERLIN TECH (DE) | 2023-05-10 | — | — | EP | disclosed |
| CN-115066263-A | Directed conjugation techniques | 克莱奥药品有限公司 | 2022-09-16 | — | — | CN | disclosed |
| US-10308595-B2 | Albicidin derivatives, their use and synthesis | Technische Universität Berlin (DE) | 2019-06-04 | — | — | US | disclosed |
| US-20150376120-A1 | ALBICIDIN DERIVATIVES, THEIR USE AND SYNTHESIS | Technische Universität Berlin (DE) | 2015-12-31 | — | — | US | disclosed |
| EP-2956774-A1 | PHOTO OR CHEMOLABILE CONJUGATES FOR MOLECULES DETECTION | Imabiotech (FR) | 2015-12-23 | — | — | EP | disclosed |
| EP-2956437-A1 | ALBICIDIN DERIVATIVES, THEIR USE AND SYNTHESIS | Centre de Cooperation Internationale en Recherche Agronomique pour le Developpement (FR) | 2015-12-23 | — | — | EP | disclosed |
| US-9102704-B2 | Synthesis method and intermediates useful in the preparation of pyrrolobenzodiazepines | SPIROGEN SARL (CH) | 2015-08-11 | — | — | US | disclosed |
| WO-2014170295-A1 | COMPOUNDS POTENTIATING THE ACTIVITY OF ANTIFUNGAL DRUGS | FUNDACIÓN MEDINA. CENTRO DE EXCELENCIA EN INVESTIGACIÓN DE MEDICAMENTOS INNOVADORES EN ANDALUCÍA (ES) | 2014-10-23 | — | — | WO | disclosed |
| US-20140275522-A1 | SYNTHESIS METHOD AND INTERMEDIATES USEFUL IN THE PREPARATION OF PYRROLOBENZODIAZEPINES | SPIROGEN SÁRL (CH) | 2014-09-18 | — | — | US | disclosed |
| US-8829184-B2 | Intermediates useful for the synthesis of pyrrolobenzodiazepines | SPIROGEN SARL (CH) | 2014-09-09 | — | — | US | disclosed |
| WO-2014125112-A1 | PHOTO OR CHEMOLABILE CONJUGATES FOR MOLECULES DETECTION | IMABIOTECH (FR) | 2014-08-21 | — | — | WO | disclosed |
| WO-2014125075-A1 | ALBICIDIN DERIVATIVES, THEIR USE AND SYNTHESIS | Technische Universität Berlin (DE) | 2014-08-21 | — | — | WO | disclosed |
| US-20130035484-A1 | INTERMEDIATES USEFUL FOR THE SYNTHESIS OF PYRROLOBENZODIAZEPINES | SPIROGEN DEVELOPMENTS SÀRL (CH) | 2013-02-07 | — | — | US | disclosed |
| EP-1392650-A2 | PROTECTED TYROSINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND USE OF THE SAME FOR PRODUCING O-(2- ?18 F]-FLUOROETHYL)-L-TYROSINE | FORSCHUNGSZENTRUM JÜLICH GMBH (DE) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002102765-A2 | PROTECTED TYROSINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND USE OF THE SAME FOR PRODUCING O-(2-[18F]-FLUOROETHYL)-L-TYROSINE | Forschungszentrum Jülich GmbH (DE) | 2002-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10308595-B2 | Albicidin derivatives, their use and synthesis | MB, ALB, BCAT2 | NPC1 4471/4885RAB9A 1659/4885CA12 1352/4885 |
| US-20150376120-A1 | ALBICIDIN DERIVATIVES, THEIR USE AND SYNTHESIS | MB, ALB, BCAT2 | NPC1 4471/4885RAB9A 1659/4885CA12 1352/4885 |
| US-20140275522-A1 | SYNTHESIS METHOD AND INTERMEDIATES USEFUL IN THE PREPARATION OF PYRROLOBENZODIAZEPINES | ORC3, OXER1, SCO2 | NPC1 2717/4885RAB9A 1392/4885CA12 2996/4885 |
| US-20130035484-A1 | INTERMEDIATES USEFUL FOR THE SYNTHESIS OF PYRROLOBENZODIAZEPINES | CYP11B2, CYP1B1, CYP11B1 | NPC1 608/4885RAB9A 923/4885CA12 3136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.